- Home
- BEAM vs TR Comparison
BEAM vs TR Comparison
Compare BEAM & TR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAM | TR |
|---|---|---|
| Founded | 2017 | 1896 |
| Country | United States | United States |
| Employees | N/A | 2100 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.2B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BEAM | TR |
|---|---|---|
| Price | $25.19 | $37.54 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $50.75 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 299.0K |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.85% |
| EPS Growth | ★ 82.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.77 | N/A |
| P/E Ratio | ★ N/A | $32.36 |
| Revenue Growth | ★ 33.33 | N/A |
| 52 Week Low | $15.60 | $34.44 |
| 52 Week High | $38.26 | $45.06 |
Technical Indicators
Market Signals| Indicator | BEAM | TR |
|---|---|---|
| Relative Strength Index (RSI) | 30.23 | 43.01 |
| Support Level | $24.80 | $36.98 |
| Resistance Level | $33.32 | $40.33 |
| Average True Range (ATR) | 1.99 | 1.15 |
| MACD | -0.94 | -0.04 |
| Stochastic Oscillator | 1.83 | 13.06 |
Price Performance
Historical ComparisonAbout BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
About TR Tootsie Roll Industries Inc.
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.